Elizabeth(Gruber)BremMD(She/Her)

PubMed

• 4 citations
  Is a BTKi or BCL2i preferable for first "novel" therapy in CLL? The case for BTKis.
  Elizabeth A Brem, Susan O'Brien
  Blood Advances. 2022-02-22
• 6 citations
  Frontline Management of CLL in 2021
  Elizabeth Brem, Susan O'Brien
  JCO Oncology Practice. 2021-07-21
• 8 citations
  SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressiv...
  Elizabeth Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti
  Journal of Geriatric Oncology. 2021-10-19

Journal Articles

• The Acute Hemolytic Anemias: The Importance of Emergency Diagnosis and Management  
  Robertson JJ, Brem E, and Koyfman A, J Emerg Med, 1/10/2017
• BOK: Oddball of the BCL-2 Family  
  Brem EA and Letai AG, Trends in Cell Biology, 1/1/2016
• Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?  
  Brem E and Davids M, Leukemia and Lymphoma, 1/1/2014
• Thrombotic Thrombocytopenic Purpura  
  Koyfman A, Brem E, and Chiang V, Pediatric Emergency Care, 1/1/2011
• Obatoclax possesses a dual Mechanism of action and potentiates the anti-tumor effects of rituximab or chemotherapy in rituximab-sensitive and -resistant lymphomas  
  Brem E, Thudium K, et al, British Journal of Haematology, 1/1/2011
• Join now to see all

Abstracts/Posters

• Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...
  Elizabeth Brem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Functional Characterization of BCL2-Family Members Identifies BH3 Mimetics As Potential Therapeutics in T-Cell Lymphomas
  Koch R, Brem E, Clark R, Kupper T, Letai A, Weinstock DM, Blood, 1/1/2016
• BH3 Mimetics May Have Utility in Cutaneous T Cell Lymphomas
  Brem E, Koch R, Clark R, Kupper T, Weinstock D, Letai A, ASH Meeting on Lymphoma Biology, 1/1/2016
• Alterations in mitochondrial priming may be a mechanism for acquired resistance to therapy in diffuse large B-cell lymphoma
  Brem E, Hernandez-Ilizaliturri FJ, Czuczman M, Rodig S, Letai A, Blood; ASH Meeting on Lymphoma Biology, 1/1/2014
• Obatoclax and Bortezomib therapy results in disruption of the p53-mediated apoptosis/autophagy pathway and is associated with potent synergistic anti-tumor activity ag...
  Hernandez-Ilizaliturri FJ, Tsio P, Campagna R, Mavis C, Riaz W, Gruber E, Gibbs J, and Czuczman M, Blood, 1/1/2009
• The BH3-Mimetic Obatoclax (GX15-070) Possesses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin’s Lymphom...
  Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak S, Hoskin P, Gruber E, and Czuczman M, Blood, 1/1/2008
• The BH3-mimetic GX15-070 Induces Autophagy-Dependent Cell Death of Therapy-Sensitive and –Resistant Aggressive B-cell non-Hodgkin’s Lymphoma (B-NHL)
  Olejniczak S, Czuczman MS, Hoskin P, Gruber E, and Hernandez-Ilizaliturri FJ, AACR Meeting Abstracts, 1/1/2008
• GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituxi...
  Gruber E, Czuczman MS, Olejniczak SH, Knight J, and Hernandez FJ, Blood, 1/1/2007
• Join now to see all

Lectures

• Statins Enhance the Efficacy of BH3 Mimetics in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Highlights of ASH 2017: Lymphomas 
  Huntington Beach, CA - 1/28/2018
• 81yoM with Aggressive Lymphoma 
  Los Angeles, CA - 1/6/2018
• Myeloma: Diagnosis, Treatments, & Support 
  Anaheim, CA - 1/3/2018
• Venous Thromboembolism 
  Anaheim, CA - 1/25/2017
• Targeting the Bcl-2 Family in Non-Hodgkin Lymphomas 
  Chicago, IL - 1/15/2017
• Primary Refractory HIV-Associated DLBCL 
  Los Angeles, CA - 1/15/2017
• Updates and Ongoing Controversies in Hodgkin Lymphoma 
  Costa Mesa, CA - 1/11/2017
• Join now to see all